Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study

Interferon beta (IFNbeta) effectively reduces disease activity in patients with multiple sclerosis (MS). Neutralizing antibodies (NAbs) can diminish or abolish the clinical efficacy of IFNbeta therapies. Biomarkers of the IFNbeta response, such as myxovirus resistance protein A (MxA), viperin, and i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2009-11, Vol.73 (18), p.1493-1500
Hauptverfasser:	PACHNER, Andrew R, WARTH, John D, PACE, Amy, GOELZ, Susan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies - immunology Biological and medical sciences Biomarkers - blood Carrier Proteins - blood Enzyme-Linked Immunosorbent Assay Female GTP-Binding Proteins - blood Humans Immunologic Factors - therapeutic use Immunomodulators Interferon-beta - immunology Interferon-beta - therapeutic use Male Medical sciences Middle Aged Multiple Sclerosis - blood Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Myxovirus Resistance Proteins Neurology Pharmacology. Drug treatments Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!